1 drug(s) with this reaction
258 total reports
Flatulence has been reported as an adverse reaction across 1 drug(s) manufactured by Ipsen Biopharmaceuticals Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 258 adverse event reports mention flatulence in connection with Ipsen Biopharmaceuticals Inc products.
This page provides a breakdown of which Ipsen Biopharmaceuticals Inc drugs are most commonly associated with flatulence, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Ipsen Biopharmaceuticals Inc drugs have flatulence listed in their FDA adverse event reports, sorted by report count:
In addition to flatulence, the following adverse reactions have been reported across Ipsen Biopharmaceuticals Inc's drug portfolio:
1 drug(s) manufactured by Ipsen Biopharmaceuticals Inc have flatulence listed in their FDA adverse event reports: LANREOTIDE ACETATE.
There are a combined 258 reports of flatulence across 1 Ipsen Biopharmaceuticals Inc drug(s) in the FDA adverse event database.